Phase 2 N=13 Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
Sarcoma
Primary: Number of Participants With Grade 3 Bilirubin — 3 participants with Grade 3 Bilirubin
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=87 Macrogol 3350-based Oral Osmotic Laxative in Preventing Cancer in Patients at Risk of Colorectal Cancer
Adenomatous Polyp · Colorectal Carcinoma
Primary: Difference (After Treatment Minus Before Treatment) of EGFR Expression — 0.17; -0.40; 0.21 ng/ml
Phase 2 N=34 Antineoplaston Therapy in Treating Children With Brain Tumors
Childhood Brain Tumors
Primary: Number of Participants With Objective Response — 1; 5; 6; 18 Participants
Phase 2 N=360 Phase 2 Trial of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
Chronic Hepatitis B
Primary: Percentage of Participants With HBeAg Seroconversion at Endpoint . — 38.8; 28.6; 20.2 percentage of participants
Phase 2 N=64 Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis
Neuropathy of Sarcoidosis
Primary: Change in Corneal Nerve Fiber Area — -64.3; 533.8; 203.8; -170.0 µm^2
Phase 2 N=209 Second Stage:Open-label Study of Therapeutic Hepatitis B Vaccine (Mimogen-based) for Chronic Hepatitis B
Chronic Hepatitis B
Primary: The Proportion of Patients About HBeAg / Anti-HBe Seroconversion at the End of the Follow-up Period — 66.7; 100; 100; 38.7 percentage of participants
Phase 2 N=14 A Trial of Extracorporeal Photopheresis, Pentostatin, and Total Body Irradiation in Patients Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation for the Treatment of Malignancies
Hematologic Malignancies
Primary: Incidence of Grade 2-4 Acute Graft Versus Host Disease Following Allogeneic Stem Cell Transplantation in Patients Randomized to Photopheresis vs. no Photopheresis — 1; 8…
Phase 2 N=77 The Effects of Metformin on Blood Vessel Structure and Function
Obesity · Hypertension · Hypercholesterolemia
Primary: Change in Arterial Stiffness Compared to Baseline — -7.2; -7.3 meters / second
Phase 2 N=137 A Study of Paclitaxel/Carboplatin With or Without Olaratumab (IMC-3G3) in Previously Untreated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) — 19.1; 19.0; 8.3 weeks — p=0.2133
Phase 2 N=38 Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in Metastatic Esophageal and Gastric Cancer
Esophageal Cancer · Stomach Cancer
Primary: 10-month Progression-Free Survival Rate — 40.0 probability (%)
Phase 2 N=7 Study of Oral Minocycline in Treating Bilateral Cystoid Macular Edema Associated With Retinitis Pigmentosa
Retinitis Pigmentosa
Primary: Change in Cystoid Macular Edema (CME) Based on Optical Coherence Tomography (OCT) Measurements in the Study Eye at 6 Months Compared to the Average of the Pre-treatment…
Phase 2 N=31 Investigating FE 202158 as Potential Primary Treatment in Patients With Early Septic Shock
Septic Shock
Primary: Percentage of Patients Maintaining Target/Adequate Mean Arterial Pressure (MAP>60 mmHg) Without Norepinephrine — 20.0; 42.9; 60.0; 7.7 Percentage of patients
Phase 2 N=118 Radiation Therapy, Temozolomide, and Lomustine in Treating Young Patients With Newly Diagnosed Gliomas
Anaplastic Astrocytoma · Central Nervous System Neoplasm · Glioblastoma
Primary: One Year Overall Survival — 0.7208 Estimated probability
Phase 2 N=29 Maximal Use Systemic Exposure (MUSE) Study of Levulan Kerastick
Keratosis, Actinic
Primary: Maximum Baseline Corrected Plasma Concentration (Cmax) for ALA — 79.85 ng/mL
Phase 2 N=70 A Trial of Single Agent Axitinib as Maintenance Therapy for Patients With First Line Metastatic Colorectal Cancer (mCRC)
Colorectal Cancer
Primary: Progression-free Survival — 8.3 months